The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis

Poly(ADP-ribose) polymerase (PARP) is involved in the pathogenesis of cell dysfunction, inflammation and organ failure during septic shock. The goal of the current study was to investigate the efficacy and safety of the clinically approved PARP inhibitor olaparib in experimental models of oxidative...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacol Res
Autors principals: Ahmad, Akbar, Vieira, Juliana de Camargo, de Mello, Aline Haas, de Lima, Thais Martins, Ariga, Suely Kubo, Barbeiro, Denise Frediani, Barbeiro, Hermes Vieira, Szczesny, Bartosz, Törö, Gábor, Druzhyna, Nadiya, Randi, Elisa B., Marcatti, Michela, Toliver-Kinsky, Tracy, Kiss, András, Liaudet, Lucas, Salomao, Reinaldo, Soriano, Francisco Garcia, Szabo, Csaba
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6662650/
https://ncbi.nlm.nih.gov/pubmed/31071432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.phrs.2019.104263
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars